These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38267304)

  • 1. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
    Kafka M; Giannini G; Artamonova N; Neuwirt H; Ofner H; Kramer G; Bauernhofer T; Luger F; Höfner T; Loidl W; Griessner H; Lusuardi L; Bergmaier A; Berger A; Winder T; Weiss S; Bauinger S; Krause S; Drerup M; Heinrich E; Schneider M; Madersbacher S; Vallet S; Stoiber F; Laimer S; Hruby S; Schachtner G; Nagele U; Lenart S; Ponholzer A; Pfuner J; Wiesinger C; Kamhuber C; Müldür E; Bektic J; Horninger W; Heidegger I
    Clin Genitourin Cancer; 2024 Apr; 22(2):458-466.e1. PubMed ID: 38267304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
    Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
    Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
    Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
    Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
    Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
    ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
    Lee A
    Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Kasparek J; Humke C; von Koskull S; Chun FKH; Banek S; Mandel P
    Urologie; 2024 Mar; 63(3):254-261. PubMed ID: 38127147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
    Saad F; Hussain MHA; Tombal B; Fizazi K; Sternberg CN; Crawford ED; Nordquist LT; Bögemann M; Tutrone R; Shore ND; Belkoff L; Fralich T; Jhaveri J; Srinivasan S; Li R; Verholen F; Kuss I; Smith MR
    Eur Urol; 2024 Oct; 86(4):329-339. PubMed ID: 38644146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
    Zhou Z; Liu S; Mei J; Liu T; Liu F; Zhang G
    Acta Oncol; 2023 Sep; 62(9):1083-1090. PubMed ID: 37548225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
    Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
    Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
    Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Fervaha G; Spratt DE; Sun Y; Kishan AU; Loblaw A; Malone S; Ong M; Saad F; Wallis CJD; Morgan SC
    Eur Urol; 2024 Jul; 86(1):10-17. PubMed ID: 38570246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
    Hussain M; Fizazi K; Shore ND; Heidegger I; Smith MR; Tombal B; Saad F
    JAMA Oncol; 2024 Jun; 10(6):807-820. PubMed ID: 38722620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
    Shore ND; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Tombal B; Nordquist L; Cookson M; Verholen F; Jhaveri J; Srinivasan S; Smith MR
    Oncologist; 2024 Mar; 29(3):235-243. PubMed ID: 37812679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.